fashion -WSS

fashion

author：entertainment 2025-09-29 01:38:37 - browse：82884

a person wearing blue dress conducts a finger prick test on another person in a home setting — coverage from STAT — Adobe

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

A systematic review by the Peterson Health Technology Institute found, though, that digital tools used to manage diabetes with the help of finger-stick blood glucose readings don’t result in clinically meaningful improvements over standard care. As a result, they don’t reduce health care spending — they drive it up.

“Most of the solutions in this category do not deliver clinical benefits that justify their cost,” Caroline Pearson, executive director of the institute, told STAT. Despite finding that some populations may benefit, the report concludes that current evidence doesn’t support broader adoption for most products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Researchers CRISPR chickens in bid to protect them from bird flu

WSS

How clinical AI models' predictive power can degrade over time

'Investigate these claims': UFO transparency at center of House hearing

The battle over 'scope creep' and who gets to be called 'doctor'

Cancer cells are shown to suck energy source from immune cells

How doctors’ personal politics affect patients

Readout LOUD podcast: Merger Mondays, Ozempic panic

focus

fashion

focus

Sports medicine is finally prioritizing gender equality

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Cancer drug shortages should be causing more outrage

European regulators recommend Amylyx's ALS drug be rejected

Alkermes shareholders re

Democrats decry new health bill for going easy on private equity

FDA approval of Sarepta Duchenne genetic therapy gives me hope

STAT Readout Newsletter: Today in biotech, life science news

Sports medicine is finally prioritizing gender equality

Humana CEO Bruce Broussard to step down in 2024

knowledge

The battle over 'scope creep' and who gets to be called 'doctor'

Akero's treatment for NASH falls short in cirrhosis study

Researchers CRISPR chickens in bid to protect them from bird flu

How doctors’ personal politics affect patients

Senate panel puts off hardest PBM reforms for another day

New lawsuit accuses health insurer Cigna of denying claims in bulk

explore

hotspot

hotspot

Wikipedia